Pfizer's Hunt for Profits Snares Hospira for $17 Billion

SUGAR LAND--February 6, 2015--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Old-guard drug giant Pfizer Incorporated (NYSE:PFE) (New York, New York) had a tough time making deals in 2014. But its $17 billion Hospira (NYSE:HSP) (Lake Forest, Illinois) buy will bolster Pfizer's own generic division, bringing sterile injectables and a biosimilars portfolio.

Within this article: Details on Pfizer's plans.

Other companies featured: AstraZeneca plc (NYSE:AZN), Teva (NYSE:TEVA), Novartis (NYSE:NVS)